Introduction
============

Bacteria belonging to the *Burkholderia* genus thrive in various ecological niches, ranging from the plant rhizosphere to the human lung, and play critical roles in ecological interactions often through the secretion of specialised metabolites.[@cit1],[@cit2] The metabolic arsenal of these bacteria is employed to eliminate other bacterial competitors and suppress plant pathogenic fungi and nematodes. In recent years various *Burkholderia* species have been shown to produce numerous specialised metabolites, many of which are assembled by polyketide synthases (PKSs) and nonribosomal peptide synthetases (NRPSs) biosynthetic assembly lines.[@cit3] Notable examples include: the respiratory toxin bongkrekic acid;[@cit4] anti-proliferative agents such as thailanstatin and spliceostatin;[@cit5],[@cit6] and the antibiotics enacyloxin IIa and gladiolin.[@cit7],[@cit8]

*Burkholderia* participate in both antagonistic and mutualistic interactions with fungi. Much of the antagonistic behaviour can be attributed to an array of antifungal compounds secreted by many *Burkholderia* species.[@cit9]--[@cit12] However, it has also been reported that *Burkholderia* strains have beneficial effects on fungi, suggestive of symbiotic, or at least mutualistic interactions.[@cit13]--[@cit15] The exemplar study of this relationship is the symbiotic pairing of *Burkholderia rhizoxinica* (since reclassified as *Paraburkholderia rhizoxinica*) and the rice seedling blight pathogen *Rhizopus microspores*. *B. rhizoxinica* was identified as the producer of the antimitotic macrolide rhizoxin, the causative agent of rice seedling blight.[@cit10],[@cit16]

In a preliminary communication, we disclosed that *Burkholderia gladioli* isolates from cystic fibrosis (CF) patients produce icosalide A1 (**1**),[@cit17] a lipopeptidiolide antibiotic originally isolated from a fungus.[@cit18] We also showed that a nonribosomal peptide synthetase (NRPS) with an unusual architecture is responsible for icosalide A1 assembly.[@cit17] Subsequently, Hertweck and co-workers reported that a *B. gladioli* endosymbiont of a beetle, along with several other *Burkholderia* species from diverse sources, also produce icosalide A1 and showed that an NRPS with the same unusual architecture as that identified in the CF isolates is responsible for its biosynthesis.[@cit19] Here we provide a full account of our work and show that a *B. gladioli* strain containing the icosalide A1 NRPS is associated with the originally reported fungal producer. Moreover, we demonstrate that a chain-initiating condensation (C~I~) domain embedded in the middle of the icosalide A1 NRPS selectively *N*-acylates a serinyl thioester covalently attached to the downstream peptidyl carrier protein (PCP) domain with a (3*R*)-3-hydroxydecanoyl panthetheine thioester, providing a mechanistic rationale for asymmetric lipopeptidiolide formation.

Results and discussion
======================

We recently reported the discovery of gladiolin, a novel macrolide antibiotic with promising activity against *Mycobacterium tuberculosis* (MIC = 0.4 μg mL^--1^) and low mammalian cell cytotoxicity, from *B. gladioli* BCC0238 (LMG-P26202).[@cit7] In the course of investigations of other specialised metabolites produced by this CF clinical isolate using UHPLC-ESI-Q-TOF-MS, compounds with the molecular formulae C~36~H~64~N~4~O~10~ and C~34~H~60~N~4~O~10~ were observed (Fig S1 and S2[†](#fn1){ref-type="fn"}). These molecular formulae correspond to a set of three structurally-related lipopeptidiolides, known as icosalides A1 (**1**), A2 (**2**) and B (**3**), reported to be produced by fungi[@cit18] ([Fig. 1A](#fig1){ref-type="fig"}).

![Structures of the icosalides, identification of the NRPS-encoding gene responsible for icosalide biosynthesis in *B. gladioli* BCC0238 and phylogenetic comparison of the *recA* sequence amplified from total DNA of the *Aureobasidium* sp. originally reported to produce icosalide A1 with various *Burkholderia* species. (A) Structures of icosalides A1 (**1**), A2 (**2**) and B (**3**). (B) Schematic representation of the ∼500 kDa NRPS encoded by the ∼15 kb *icoA* gene. Domain abbreviations are as follows: C, condensation; A, adenylation; PCP, peptidyl carrier protein; TE, thioesterase. (C) Extracted ion chromatogram at *m*/*z* 713.46 ± 0.02, corresponding to \[M + H\]^+^ for icosalide A1, from LC-MS analyses of extracts of agar-grown cultures of *B. gladioli* BCC0238 (top) and *B. gladioli* BCC0238 Ω*icoA*, in which the NRPS-encoding gene has been disrupted (bottom). (D). Phylogenetic comparison of the *recA* sequence amplified from the total DNA extract of *Aureobasidium* sp. MSX 59166 (labelled 'icosalide producer') with *recA* sequences from 24 representative *Burkholderia* species, showing that the fungus-associated bacterium clades with *Burkholderia gladioli*. The scale bar indicates the number of substitutions per site.](c8sc04897e-f1){#fig1}

The icosalides possess similar 20-membered lipopeptidiolide structures consisting of two serine, leucine and 3-hydroxy acid residues. In icosalide A1 (**1**), one of the leucine residues is [d]{.smallcaps}-configured, whereas all of the amino acid residues in icosalides A2 (**2**) and B (**3**) are [l]{.smallcaps}-configured. Icosalides A1 (**1**) and A2 (**2**) both contain one eight-carbon and one ten-carbon 3-hydroxy acid residue, whereas icosalide B (**3**) contains two eight-carbon 3-hydroxy acid residues. The incorporation of a [d]{.smallcaps}-leucine residue into icosalide A1 (**1**) has a dramatic effect on its biological activity. While icosalide A1 (**1**) is active against *Streptococcus pyogenes* (MIC: 8--16 μg mL^--1^), icosalides A2 (**2**) and B (**3**) do not show any antibacterial activity but are cytotoxic towards replicating MDCK cells (CC~50~: 5 μg mL^--1^).[@cit18]

The compound with the molecular formula C~36~H~64~N~4~O~10~ was purified using semi-preparative HPLC and its planar structure was shown to be identical to that of icosalide A1 (**1**) using a combination of ^1^H, ^13^C and HMBC NMR experiments (Fig. S3 and Table S1[†](#fn1){ref-type="fn"}). The absolute stereochemistry of the amino acid residues in the purified compound was determined *via* saponification of the esters, followed by semi-preparative HPLC purification and MS analysis of the resulting pair of 3-hydroxyacyl-dipeptides, acid hydrolysis to liberate the constituent amino acids, derivatisation using Marfey\'s reagent and comparison with the corresponding [l]{.smallcaps} and [d]{.smallcaps}-configured leucine and serine standards (Fig. S4 and S5[†](#fn1){ref-type="fn"}). This revealed that the Leu-2 residue is [d]{.smallcaps}-configured, confirming the identity of the metabolite produced by *B. gladioli* as icosalide A1 (**1**). The production level of the compound with the molecular formula C~34~H~60~N~4~O~10~ was too low to permit characterisation by NMR spectroscopy (Fig. S6[†](#fn1){ref-type="fn"}), but it seems likely that this has the same planar structure as icosalide B (**3**). The activity of purified icosalide A1 (**1**) against several Gram-positive and Gram-negative bacteria, including the ESKAPE panel of pathogens, and *Candida albicans* was tested. Modest activity against *E. faecium* (MIC: 16 μg mL^--1^) was observed (Table S2[†](#fn1){ref-type="fn"}).

Inspection of putative specialised metabolite biosynthetic gene clusters in the previously reported genome sequence of *B. gladioli* BCC0238,[@cit7] identified a single ∼15 kb gene (*icoA*) on chromosome 2 encoding a nonribosomal peptide synthetase (NRPS) with the requisite module and domain organisation for icosalide assembly ([Fig. 1B](#fig1){ref-type="fig"}). This NRPS contains four adenylation (A) domains, two of which are predicted to be specific for [l]{.smallcaps}-leucine and two for [l]{.smallcaps}-serine[@cit20] (Table S3[†](#fn1){ref-type="fn"}). It also contains five condensation (C) domains and a thioesterase (TE) domain, which together account for the four amide and two ester bond-forming reactions required to assemble the lipopeptidiolide structure of the icosalides[@cit21] ([Fig. 2A](#fig2){ref-type="fig"}). We identified *icoA* in the genomes of several other *B. gladioli* isolates (BCC0252, BCC1677, BCC1698 and BCC1720), all of which were shown to produce icosalide A1 (**1**). In contrast, no icosalide A1 (**1**) production was detected in *B. gladioli* BCC1713 (Fig. S7[†](#fn1){ref-type="fn"}), which is lacking *icoA*. These data are consistent with the hypothesis that the NRPS encoded by *icoA* is responsible for icosalide biosynthesis. To verify this, we inactivated the *icoA* gene in *B. gladioli* BCC0238 using insertional mutagenesis. UHPLC-ESI-Q-TOF-MS analysis of extracts from the *icoA* mutant confirmed that it is no longer able to produce icosalides ([Fig. 1C](#fig1){ref-type="fig"}).

![Proposed mechanism for assembly of icosalide A1 (**1**) by IcoA. Domain and module organisation of the NRPS, showing the PCP-bound thioester intermediates proposed to be formed by each module. The C~I~ domains initiate lipopeptide chain assembly by *N*-acylating the aminoacyl thioesters attached to the downstream PCP domains with 3-hydroxyacyl thioester intermediates in fatty acid biosynthesis. Abbreviations are as follows: A, adenylation domain; C~I~, chain initiating condensation domain; C~E~, bifunctional epimerisation--condensation domain; ^L^C~L~, condensation domain that catalyses condensation of [l]{.smallcaps}-configured aminoacyl donor and acceptor substrates; PCP, peptidyl carrier protein domain; TE, thioesterase domain. The residues used to predict the substrate specificity of A-domains are shown in Table S3[†](#fn1){ref-type="fn"}.](c8sc04897e-f2){#fig2}

Icosalide A1 (**1**) was originally isolated from extracts of an *Aureobasidium* species fungus (strain MSX 59166), whereas icosalides A2 (**2**) and B (**3**) were isolated from a second less well characterized fungal species (MSX 74159).[@cit18] The data presented above suggested that *B. gladioli* bacteria associated with these fungi might be the true producers of the icosalides isolated from them. To investigate this hypothesis, total DNA from the originally reported icosalide A1 (**1**) producer, *Aureobasidium* sp. MSX 59166, was screened by PCR for orthologues of *icoA* and the bacterial housekeeping gene *recA*. In both cases, we obtained amplimers of the expected size (Fig. S8[†](#fn1){ref-type="fn"}), confirming that a bacterium, likely harbouring an *icoA* orthologue, is associated with the fungus. *Burkholderia* species can be unambiguously identified *via* phylogenetic comparison of their *recA* sequences.[@cit22] Thus, we compared the sequence of the *recA* amplimer with the sequences of *recA* genes from 25 representative *Burkholderia* species. This showed that the *Aureobasidium*-associated bacterium is *B. gladioli* ([Fig. 1D](#fig1){ref-type="fig"}). Illumina sequencing of the total DNA from the *Aureobasidium* sp. allowed an approximately 1 Mb contiguous sequence of bacterial DNA, encompassing the *icoA* orthologue, to be assembled (Fig. S9[†](#fn1){ref-type="fn"}). Comparison of this contiguous sequence with the corresponding region of the *B. gladioli* BCC0238 genome showed a high degree of synteny (Fig. S9[†](#fn1){ref-type="fn"}), confirming that the *Aureobasidium* sp. harbours a *B. gladioli* strain containing an *icoA* orthologue. Although a Gram-negative bacterium could be isolated from the *Aureobasidium* sp., it quickly lost viability and was not identifiable.

Inspection of the structure of icosalide A1 (**1**) suggests it is assembled *via* initial formation of 3-hydroxyoctanoyl-[d]{.smallcaps}-leucinyl-[l]{.smallcaps}-serinyl and 3-hydroxydecanoyl-[l]{.smallcaps}-serinyl-[l]{.smallcaps}-leucinyl thioesters, which are joined *via* a pair of ester linkages to form the lipopeptidiolide. To gain insight into the role played by each of the five C domains of IcoA in the biosynthesis of icosalide A1 (**1**), we carried out phylogenetic analyses.[@cit23] These indicated that the first and fourth domains group with chain initiating (C~I~) domains, which are typically located at the N-terminus of the first module in NRPSs responsible for lipopeptide biosynthesis and initiate chain assembly *via N*-acylation of the amino acyl thioester bound to the downstream PCP domain with a fatty acyl thioester. The third and fifth C domains of IcoA belong to the ^L^C~L~ group, which catalyse formation of a peptide bond between [l]{.smallcaps}-configured amino acyl thioesters attached to the upstream and downstream PCP domains. In contrast, the second C domain of IcoA clusters with bifunctional epimerisation--condensation (C~E~) domains, which catalyse epimerisation of the α-carbon in the aminoacyl thioester attached to the upstream PCP domain, followed by condensation of the resulting [d]{.smallcaps}-configured intermediate with an [l]{.smallcaps}-aminoacyl thioester attached to the downstream PCP domain. These C domain functional assignments led us to propose that modules 1 and 2 of IcoA are responsible for assembly of the 3-hydroxyoctanoyl-[d]{.smallcaps}-leucinyl-[l]{.smallcaps}-serinyl thioester intermediate in icosalide A1 (**1**) biosynthesis ([Fig. 2](#fig2){ref-type="fig"}). The C~I~ domain appended to the N-terminus of module 1 initiates chain assembly *via N*-acylation of the [l]{.smallcaps}-leucinyl thioester attached to the module 1 PCP domain with a 3-hydroxyoctanoyl thioester, likely donated by the primary metabolic fatty acid synthase (FAS). The C-domain in module 2 then catalyses epimerisation of the resulting *N*-acyl-leucinyl thioester, followed by condensation with the [l]{.smallcaps}-serinyl thioester attached to the module 2 PCP domain. Module 3 of IcoA is very unusual, because it contains an ^L^C~L~ domain directly followed by a C~I~ domain. We hypothesize that the C~I~ domain in this module catalyses a second chain initiation event, resulting in *N*-acylation of the [l]{.smallcaps}-serinyl thioester attached to the downstream PCP domain with a 3-hydroxydecanoyl group, again likely provided by the primary metabolic FAS. The ^L^C~L~ domain then catalyses acylation of the hydroxyl group in the resulting 3-hydroxydecanoyl-[l]{.smallcaps}-serinyl thioester with the 3-hydroxyoctanoyl-[d]{.smallcaps}-leucinyl-[l]{.smallcaps}-serinyl thioester attached to the module 2 PCP domain. Elongation of the resulting intermediate with the [l]{.smallcaps}-leucinyl thioester attached to the PCP domain in module 4, catalysed by the upstream ^L^C~L~ domain, followed by lactonisation catalysed by the downstream TE domain, yields icosalide A1 ([Fig. 2](#fig2){ref-type="fig"}).

To the best of our knowledge, initiation of chain assembly by an embedded C~I~ domain like the one found in module 3 of IcoA is without precedent in NRPS enzymology. We thus sought to experimentally validate the proposed chain initiation reaction *in vitro* by overproducing the C~I~-A-PCP tri-domain from module 3 of IcoA in *E. coli*. The resulting N-terminal His~6~ fusion protein, was purified to homogeneity using immobilised metal-ion affinity chromatography and the hexahistidine tag was cleaved using thrombin (Fig. S10[†](#fn1){ref-type="fn"}). ESI-Q-TOF-MS analysis showed that the PCP domain of this protein had been partially converted to the *holo* form by an *E. coli* phosphopantetheinyl transferase (Fig. S10[†](#fn1){ref-type="fn"}). To fully convert the PCP domain into the *holo* form we incubated the protein with purified recombiant Sfp, a substrate tolerant phosphopantetheinyl transferase from *B. subtilis*,[@cit24] and coenzyme A.

The *holo*-C~I~-A-PCP tri-domain was incubated with ATP, [l]{.smallcaps}-Ser and 3*R*-configured 3-hydroxyoctanoyl or 3-hydroxydecanoyl-panthetheine thioesters, which mimic the (3*R*)-3-hydroxyoctanoyl and (3*R*)-3-hydroxydecanoyl-ACP intermediates in fatty acid biosynthesis proposed to be intercepted by the C~I~ domains in modules 1 and 3, respectively, of the NRPS. UHPLC-ESI-Q-TOF-MS analysis of the C~I~-A-PCP tri-domain showed mass shifts consistent with the formation of serinyl, 3-hydroxyoctanoyl-serinyl and 3-hydroxydecanoyl-serinyl PCP-thioesters ([Fig. 3](#fig3){ref-type="fig"}). When the C~I~-A-PCP tri-domain was replaced with a mutant containing an Ala residue in place of the active site His residue in the C~I~ domain, only trace amounts of products were formed ([Fig. 3](#fig3){ref-type="fig"}).

![*In vitro* reconstitution of aminoacyl thioester formation and *N*-acylation by the C~I~-A-PCP tridomain from module 3 of IcoA. Deconvoluted mass spectra of IcoA module 3 C~I~-A-PCP tri-domain. (A) Resulting from incubation with ATP, [l]{.smallcaps}-Ser and (3*R*)-3-hydroxyoctanoyl (top), (3*R*)-3-hydroxydecanoyl (middle), or (3*R*)-3-hydroxyoctanoyl and (3*R*)-3-hydroxydecanoyl (bottom) pantetheine thioesters. (B) Following incubation with ATP, [l]{.smallcaps}-Ser and (3*S*)-3-hydroxyoctanoyl (top), or (3*S*)-3-hydroxydecanoyl (bottom) pantetheine thioesters. (C) Resulting from incubation of the H164A mutant with ATP, [l]{.smallcaps}-Ser and (3*R*)-3-hydroxyoctanoyl (top), or (3*R*)-3-hydroxydecanoyl (bottom) pantetheine thioesters. Dashed lines indicate the peaks corresponding to each condensed species, and the *holo*- and [l]{.smallcaps}-Ser-loaded species are labelled as indicated in the bottom right corner. Loading of [l]{.smallcaps}-Ser onto the PCP domain results in an 87 Da mass increase. For the wild type IcoA C~I~-A-PCP tri-domain, *N*-acylation of the serinyl-PCP thioester with the (3*R*)-3-hydroxyoctanoyl and (3*R*)-3-hydroxydecanoyl thioesters resulted in additional 142 and 170 Da mass increases, respectively. Analogous mass increases were observed when the (3*S*)-3-hydroxyoctanoyl and (3*S*)-3-hydroxydecanoyl thioesters were used, but the levels of product formation were lower, indicating that the C~I~ domain prefers *R*-configured 3-hydroxyacyl thioesters. A small amount of product formation was observed when the H164A mutant of the IcoA C~I~-A-PCP tri-domain was used in place of the wild type protein, due to uncatalysed *N*-acylation of the serinyl thioester with the (3*R*)-3-hydroxyoctanoyl and (3*R*)-3-hydroxydecanoyl thioesters.](c8sc04897e-f3){#fig3}

Icosalide A1 contains an *N*-((3*R*)-3-hydroxydecanoyl)-[l]{.smallcaps}-serine residue.[@cit19] The module 3 C~I~ domain is thus expected to accept 3-hydroxydecanoyl thioesters in preference to 3-hydroxyoctanoyl thioesters. To test this hypothesis, we incubated the *holo*-C~I~-A-PCP tri-domain with ATP, [l]{.smallcaps}-Ser and equimolar mixture of the 3*R*-configured 3-hydroxyoctanoyl and 3-hydroxydecanoyl-panthetheine thioesters. UHPLC-ESI-Q-TOF-MS analysis showed that only the product resulting from condensation with the 10-carbon thioester is formed ([Fig. 3](#fig3){ref-type="fig"}). The incorporation of 3-hydroxyoctanoyl-[l]{.smallcaps}-serinyl-[l]{.smallcaps}-leucine into icosalide A2 (**2**), the major icosalide produced by the MSX 74159 fungus, suggests that the NRPS responsible for assembly of this metabolite contains an embedded C~I~ domain with a preference for 8-carbon thioesters. It would therefore be interesting to investigate the mechanisms underlying icosalide A2 biosynthesis.

The module 3 C~I~ domain might also be expected to prefer *R*-configured 3-hydroxyacyl thioesters to their *S*-configured counterparts. (Note, however, that the ketoreductase in bacterial fatty acid biosynthesis produces exclusively 3*R*-configured 3-hydroxyacyl-ACP thioester intermediates.[@cit25] There may therefore be no selective pressure to drive the evolution of stereoselectivity in C~I~ domains.) To investigate whether the module 3 C~I~ domain is stereoselective, we incubated the *holo*-C~I~-A-PCP tri-domain with ATP, [l]{.smallcaps}-Ser and (3*S*)-3-hydroxyoctanoyl or (3*S*)-3-hydroxydecanoyl-panthetheine thioesters. Although the reaction with the 10-carbon thioester resulted in a significant degree of product formation, it was clearly less efficient than the reaction with the corresponding 3*R*-configured thioester ([Fig. 3](#fig3){ref-type="fig"}). In contrast, only trace amounts of product were formed in the reaction employing the eight-carbon thioester ([Fig. 3](#fig3){ref-type="fig"}). Thus, the C~I~ domain appears to possess a moderate to high degree of stereoselectivity, depending on the carbon chain length of the substrate. Overall, our data show that the module 3 C~I~ domain of IcoA plays a key role in initiating the assembly of the (3*R*)-3-hydroxydecanoyl-[l]{.smallcaps}-serinyl-[l]{.smallcaps}-leucinyl moiety of icosalide A1.

Conclusions
===========

We have shown that the "fungal" antibiotic icosalide A1 (**1**), originally isolated from an *Aureobasidium* sp., is produced by a *B. gladioli* strain closely associated with the fungus. In addition, we have shown that *B. gladioli* isolates from a range of sources, including CF lung infections, mushroom rot and insects also produce this metabolite. Comparative genome sequence analysis coupled with genetic manipulation allowed identification of a gene encoding the NRPS responsible for icosalide A1 biosynthesis. The third module of this NRPS has a very unusual architecture, containing a putative chain-initiating C~I~ domain in addition to a chain elongating ^L^C~L~ domain. Intact protein mass spectrometry showed that this C~I~ domain catalyses selective *N*-acylation of a serinyl thioester bound to the module 3 PCP domain with a (3*R*)-3-hydroxydecanoyl thioester. Thus, the asymmetric lipopeptidiolide core of icosalide A1 (**1**) is assembled by a unique mechanism involving two distinct chain initiation events on a single NRPS subunit.
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